Trials / Terminated
TerminatedNCT04472494
Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise
Phase 2, Randomized, Double-Blind Placebo Controlled Study of Intravenous Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of intravenous abatacept administered to hospitalized COVID-19 participants with respiratory compromise.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Abatacept | Specified dose on specified days |
| OTHER | Placebo | Specified dose on specified days |
Timeline
- Start date
- 2020-10-14
- Primary completion
- 2021-08-12
- Completion
- 2021-09-13
- First posted
- 2020-07-15
- Last updated
- 2022-10-07
- Results posted
- 2022-10-07
Locations
10 sites across 2 countries: United States, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04472494. Inclusion in this directory is not an endorsement.